Psychiatric medication management for Highland Beach — measurement-based, in-person.

For Highland Beach residents in Bel Lido Isle, Toscana, or Boca Cove, RECO Integrated Psychiatry sits twelve minutes south on A1A — a shorter drive than most Boca practices and a fundamentally different clinical model. Initial evaluations run 60 to 90 minutes with a board-certified psychiatrist and produce a documented DSM-5-TR formulation; follow-ups are anchored to PHQ-9 and GAD-7 trajectories rather than clinical impression. When first-line SSRIs and SNRIs are inadequate, the same practice offers augmentation, TMS, and Spravato under one roof.

Highland Beach is the narrow oceanfront strip between Delray and Boca Raton — roughly twelve minutes north along A1A to RECO Integrated Psychiatry’s Delray Beach campus. For residents of Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, and the Penthouse Condominiums, the clinical density concentrated at RECO delivers what general behavioral-health practices in Boca structurally cannot: specialist-level psychiatric medication management, on-site TMS and Spravato, and full DSM-5-TR diagnostic workups conducted by board-certified psychiatrists rather than triaged through a fifteen-minute primary-care refill.

What a real psychiatric evaluation actually covers

The initial evaluation runs 60 to 90 minutes and produces a documented DSM-5-TR diagnostic formulation, not a symptom checklist attached to a prescription. The medication history captures every prior psychotropic trial with dose, duration, and the specific reason for discontinuation — because “sertraline didn’t work” at 50 mg for three weeks is not a failed SSRI trial and dictates a fundamentally different next step than a genuine non-response at 200 mg over ten weeks.

Family psychiatric history is documented across first-degree relatives, and any adult presenting with “depression” or “anxiety” is actively screened for bipolar spectrum illness, adult ADHD, and obsessive-compulsive disorder using the MDQ, ASRS, and Y-BOCS respectively. A substance use screen is standard, and trauma history is taken where clinically indicated. Baseline laboratory studies — CBC, CMP, TSH, B12, folate, vitamin D, and a lipid panel — are ordered where the differential or medication plan requires them. This is the work primary care does not have the time or credentialing to complete in a twenty-minute visit.

Measurement-based care and why it changes outcomes

Every follow-up at RECO is anchored to numerical outcome data. PHQ-9 for depressive symptom burden, GAD-7 for generalized anxiety, MDQ for bipolar screening, ASRS for adult ADHD, and Y-BOCS for OCD are completed by the patient before the appointment, scored during the visit, and plotted over time so that pharmacologic decisions are made against a trajectory rather than the ambient mood of a single Tuesday morning.

The published literature on measurement-based care is unambiguous: symptom rating scales tracked visit-over-visit produce meaningfully better response and remission rates than clinical impression alone, particularly in the augmentation and switching decisions that define real-world treatment-resistant depression. A patient who reports feeling “about the same” but whose PHQ-9 has moved from 19 to 11 is responding and should hold the course; a patient who reports feeling “great today” but whose GAD-7 is unchanged at 16 needs a different plan. Measurement-based care removes that ambiguity from the room.

The pharmacologic toolkit beyond the first two SSRIs

First-line pharmacotherapy is not controversial. SSRIs and SNRIs — sertraline, escitalopram, venlafaxine, duloxetine — anchor treatment for major depression and most anxiety disorders. Stimulants and atomoxetine anchor ADHD. Mood stabilizers and second-generation antipsychotics — lithium, lamotrigine, quetiapine, aripiprazole, olanzapine — anchor bipolar disorder. SSRIs paired with a referral for exposure and response prevention anchor OCD.

The value of a specialty psychiatry practice is what happens after first-line pharmacotherapy fails. RECO’s psychiatrists move through augmentation strategies — aripiprazole 2 to 5 mg, low-dose lithium, T3 thyroid augmentation with liothyronine, buspirone for residual anxiety — before defaulting to a fourth SSRI switch. MAOIs remain on the table for genuinely refractory depression. Pharmacogenomic testing through GeneSight or Genomind is used selectively in complex or intolerant cases rather than reflexively.

When two adequate antidepressant trials have failed at therapeutic dose and duration, the conversation moves to interventional treatment: rTMS delivered at 120 percent of motor threshold across 3000 pulses per session over a 36-session standard course, or esketamine (Spravato) under REMS-monitored administration. Adjunctive psychotherapy — CBT, ACT, EMDR, or DBT skills — is coordinated in parallel where the clinical picture calls for it.

Monitoring: the labs, the metabolic panel, the drug levels

Psychotropic medications require monitoring, and that monitoring is built into the visit cadence rather than deferred to whether the patient remembers to ask. Lithium requires a baseline TSH, creatinine, calcium, and pregnancy status, then twelve-hour post-dose lithium levels quarterly alongside renal and thyroid function every six to twelve months. Valproate requires baseline LFTs, a CBC with platelets, and periodic drug levels.

Second-generation antipsychotics — quetiapine, aripiprazole, olanzapine — require baseline and at-minimum-annual metabolic panels: fasting glucose or HbA1c, lipid panel, weight, waist circumference, and blood pressure. Stimulants require a cardiovascular history at baseline and blood pressure and pulse checks at every visit. Clozapine, where indicated, follows the REMS-mandated ANC schedule without exception. None of this is optional, and none of it depends on the patient volunteering the question at the end of a follow-up.

What to expect on your first visit

The intake questionnaire, PHQ-9, and GAD-7 are completed online at least twenty-four hours before the appointment; any diagnosis-specific scale — MDQ, ASRS, Y-BOCS — is added as appropriate. The initial visit itself is a single 60- to 90-minute appointment with the psychiatrist, not a triage call routed to a mid-level for later handoff.

By the end of that first visit, the patient leaves with a written diagnostic formulation, a specific medication plan with dose range and titration schedule, any lab orders required to safely initiate or continue treatment, and a follow-up scheduled within two to four weeks. Prior psychiatric records are reviewed before the appointment when the patient has signed a release, so the visit is not consumed re-collecting a history the patient has already given twice this year.

Insurance and admissions from Highland Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Benefits are verified in writing before the first appointment so patients receive a specific quote for copay, coinsurance, and remaining deductible before they incur charges rather than after. Out-of-network benefits and transparent self-pay rates are available; a superbill is provided on request for reimbursement filings.

From Highland Beach the drive is approximately seven miles and twelve minutes south on State Road A1A or Federal Highway (US-1), and on-site parking is available. Established patients whose clinical picture and controlled-substance status permit remote management may complete routine follow-ups via telepsychiatry — for many Bel Lido or Toscana residents, that reduces a stable medication-management follow-up to a fifteen-minute video visit from home while preserving in-person appointments for the initial evaluation, meaningful medication changes, and indicated quarterly review.

Serving residents of: Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, Penthouse.